On August 3, 2020 Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, reported the launch of SIROS, an innovative system for the delivery of SIR-Spheres Y-90 resin microspheres (Press release, Sirtex Medical, AUG 3, 2020, View Source [SID1234562719]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SIROS offers a visual, intuitive and versatile option for interventional radiologists to deliver SIR-Spheres to patients with liver cancer. With the system’s visually controlled administration, physicians can determine and adjust the precise quantity and speed of SIR-Spheres microspheres delivery. Additionally, the system is designed to be simple to use yet versatile enough to allow expanded options for patient-tailored delivery.

SIROS’ intuitive design features a peel-and-place tubing set, a proprietary needleless D-Vial specifically designed to suspend SIR-Spheres into a vortex that may allow for a more even distribution, and a locking cover to safely secure the microspheres during delivery. A three-step setup further provides quick and simple administration and disposal.

"SIROS brings world-class expertise and innovation together to provide interventional radiologists with the support and technology they need to treat patients with liver cancer," said Kevin R. Smith, Chief Executive Officer of Sirtex. "As established leaders in the industry for more than 20 years, we are pleased to add SIROS to our expanding portfolio of technology designed to advance patient care."